Screener
Gyre Therapeutics, Inc. GYRE Total Equity
Total Equity at other companies
Other financials
Where this comes from
Reported directly by Gyre Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:StockholdersEquity.
The source filing: Gyre Therapeutics, Inc.’s 10-Q, filed August 7, 2026. Open the filing →
- Filed
- Aug 7, 2026, 5:00 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-340448
FAQ
- What is Gyre Therapeutics, Inc.'s total equity?
- Gyre Therapeutics, Inc. (GYRE) reported total equity of $107.93M in Q2 2026.
- How has Gyre Therapeutics, Inc.'s total equity changed year-over-year?
- Gyre Therapeutics, Inc.'s total equity increased by 17.3% year-over-year, from $92.03M to $107.93M.
- What is the long-term trend for Gyre Therapeutics, Inc.'s total equity?
- Over 5 years (2020 to 2025), Gyre Therapeutics, Inc.'s total equity has grown at a -3.9% compound annual growth rate (CAGR), from $76.07M to $62.5M.
- What does total equity mean?
- Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.
Ask your AI about Gyre Therapeutics, Inc.'s total equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude